SCHEMBL16748586

SCHEMBL16748586

COc1ccc(Nc2nc(N)nc(-n3c(C)nc4c(F)cc(F)cc43)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
ALDH1A1 P00352 3/20 0.44
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
JAK2 O60674 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
SLC29A2 Q14542 1/20 0.42
SLC29A1 Q99808 1/20 0.42
CHRNA7 P36544 1/20 0.42
MAPK1 P28482 2/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748591 0.90 CYBB (0.44) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL16740775 0.89 BMI1 (0.50) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL16748597 0.89 MAPT (0.44) MAPTALDH1A1RAB9AKDM4ENPC1
Hydrochloric Acid SCHEMBL16740800 0.89 BMI1 (0.49) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL16748436 0.88 AGPAT2 (0.42) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL16748592 0.88 EGFR (0.41) MAPTALDH1A1RAB9ANPC1JAK2
SCHEMBL16740743 0.87 SLC29A2 (0.47) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL16740870 0.86 BMI1 (0.48) MAPTMEN1KMT2ALMNAAPP
SCHEMBL16748450 0.86 BMI1 (0.52) MAPTALDH1A1RAB9AKDM4ENPC1
SCHEMBL15742513 0.85 AURKA (0.40) MAPTALDH1A1RAB9APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B MAPT 4579/4885ALDH1A1 1740/4885RAB9A 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.